Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03606057 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
NCT03606057 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 188 participants.
The verdict
NCT03606057, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects on placebo-corrected change from baseline QT interval corrected for individual heart rate (QTcI) of JNJ-64565111 close to steady state on Day 26 and on electrocardiogram morphology at supratherapeutic exposures in otherwise healthy overweight/obese adults after 4 weeks of treatment with JNJ 64565111 administered subcutaneously once weekly.
Interventions
- DRUG Moxifloxacin
- DRUG JNJ-64565111
- DRUG Moxifloxacin-matching Placebo
- DRUG JNJ-64565111-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2019-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03606057
The ClinicalTrials.gov registry entry for NCT03606057 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin is the first listed.
NCT03606057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03606057 about?
NCT03606057 is a clinical study titled "A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)". The purpose of this study is to assess the effects on placebo-corrected change from baseline QT interval corrected for individual heart rate (QTcI) of JNJ-64565111 close to steady state on Day 26 and on electrocardiogram morphology at supratherapeutic exposures in otherwise healthy overweight/obese ...
What is the current status of trial NCT03606057?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2018-07-13. Estimated completion is 2019-02-28.
What interventions are being tested in trial NCT03606057?
The interventions under investigation include: Moxifloxacin (DRUG), JNJ-64565111 (DRUG), Moxifloxacin-matching Placebo (DRUG), JNJ-64565111-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT03606057?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.